[HTML] nih.gov

[HTML][HTML] Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct …

H Qin, L Yang, JA Chukinas, NN Shah… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Background Successful development of chimeric antigen receptor (CAR) T cell
immunotherapy for children and adults with relapsed/refractory acute myeloid leukemia …
被引用次数：44 相关文章

Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design

H Qin, L Yang, JA Chukinas, N Shah… - Journal for …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Successful development of chimeric antigen receptor (CAR) T cell
immunotherapy for children and adults with relapsed/refractory acute myeloid leukemia …

Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.

H Qin, L Yang, JA Chukinas, N Shah… - … for Immunotherapy of …, 2021 - europepmc.org
Background Successful development of chimeric antigen receptor (CAR) T cell
immunotherapy for children and adults with relapsed/refractory acute myeloid leukemia …

Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design

H Qin, L Yang, JA Chukinas, N Shah… - Journal for …, 2021 - search.proquest.com
Background Successful development of chimeric antigen receptor (CAR) T cell
immunotherapy for children and adults with relapsed/refractory acute myeloid leukemia …
[HTML] bmj.com

[HTML][HTML] Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct …

H Qin, L Yang, JA Chukinas, NN Shah… - … for ImmunoTherapy of …, 2021 - jitc.bmj.com
Background Successful development of chimeric antigen receptor (CAR) T cell
immunotherapy for children and adults with relapsed/refractory acute myeloid leukemia …